Data updated: May 26, 2026
Alprolix (coagulation factor ix (recombinant), fc fusion protein)
Approved 2014-03-27
1
Indication
--
Phase 3 Trials
12
Years on Market
Details
- Status
- Prescription
- First Approved
- 2014-03-27
- Patent Cliff
- 2021
- Revenue
- $165M (Q4-2025)
- Routes
- Intravenous
- Dosage Forms
- For Injection
Companies
Active Ingredient: Coagulation Factor IX (Recombinant), Fc Fusion Protein , Coagulation Factor IX (Recombinant), Fc Fusion Protein , Coagulation Factor IX (Recombinant), Fc Fusion Protein , Coagulation Factor IX (Recombinant), Fc Fusion Protein , Coagulation Factor IX (Recombinant), Fc Fusion Protein , Coagulation Factor IX (Recombinant), Fc Fusion Protein
Website: ↗
Alprolix Approval History
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
1 FDA actions from 2014 to 2014
Mar 2014 ORIGINAL
Update · CBER biologic (Purple Book)
What Alprolix Treats
1 FDA approvalsOriginally approved for its first indication in 2014 .
- Other (1)
Other
(1 approval)- • Approved indication (Mar 2014)
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
|
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
Alprolix FDA Label Details
Pro Intelligence Preview
Deep insights for Alprolix
Revenue Insights
- • Q4-2025: $165M
- • Historical trend analysis
Patent Timeline
- • Cliff: 2021
- • Generic/biosimilar risk
Trial Analysis
- • Clinical trial tracking
- • Development stage analysis
Competitive Landscape
- • Competitor tracking
- • Same target/indication analysis
Unlock Full Intelligence
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.